Not provided
Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| R01CA112028 | U.S. NIH Grant/Contract | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Johns Hopkins University | OTHER |
| National Cancer Institute (NCI) | NIH |
| Wake Forest University | OTHER |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The overall purpose of this research is to determine if certain genes increase the chance of developing prostate cancer and once diagnosed increase the chance of the prostate cancer spreading to other parts of the body.
DNA will be isolated from each person and then studied for the presence of certain genes that may increase the chance of developing prostate cancer. Certain genes will also be studied in patients with known prostate cancer to determine if they increase the chance of cancer spreading to other parts of the body and decrease one's chance of being cured. Small differences in genes can slightly affect their ability to function. While these differences are normal, they may influence the way the cancer responds to therapy. An understanding of which genes increase (or decrease) the chance of being cured of a disease, such as prostate cancer, will improve our ability to take care of patients more effectively.
A second purpose of this study is to collect blood and cancer tissue for future studies. While the small differences in genes may be the best marker of bad cancer, it is also possible that proteins in blood or tumor may be a better marker.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Newly diagnosed patients | Patients with newly diagnosed prostate cancer. |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Ability to recognize increased risk of metastatic prostate cancer based on specific genetic polymorphisms. | At the time of prostate cancer diagnosis |
| Measure | Description | Time Frame |
|---|---|---|
| Ability to predict risk for treatment failure based on analysis of specific polymorphisms. | At the time of prostate cancer diagnosis |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Patients with newly diagnosed prostate cancer are being recruited for this study from Siteman Cancer Center radiation oncology, medical oncology and urology clinics.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Bettina Drake, PhD | Washington University School of Medicine | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Washington University School of Medicine | St Louis | Missouri | 63110 | United States |
Not provided
| ID | Term |
|---|---|
| D011471 | Prostatic Neoplasms |
| ID | Term |
|---|---|
| D005834 | Genital Neoplasms, Male |
| D014565 | Urogenital Neoplasms |
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
Not provided
Not provided
Not provided
Not provided
Not provided
Whole blood, serum, white cells, prostate tissue.
| D005832 |
| Genital Diseases, Male |
| D000091662 | Genital Diseases |
| D000091642 | Urogenital Diseases |
| D011469 | Prostatic Diseases |
| D052801 | Male Urogenital Diseases |